Pluristem Initiates Trial in South Korea - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Pluristem Therapeutics Inc. ( PSTI ) announced that it has initiated a phase II trial in South Korea to evaluate PLacental eXpanded (PLX) cells for the treatment of intermittent claudication (IC).

The study is being conducted by partner CHA Bio & Diostech.

We note that CHA Bio & Diostech has an exclusive licensing agreement with Pluristem to evaluate PLX cells for peripheral artery disease (PAD) in South Korea.

As per the terms of the agreement, both Pluristem and CHA will enter into a joint venture to share the revenues and income generated through sales of PLX cell therapies in the South Korean market if and when a candidate receives approval in South Korea.

We remind investors that Pluristem received approval from the South Korean Ministry of Food and Drug Safety to conduct trials in South Korea evaluating the use PLX cells in May 2014.

Meanwhile, trials on PLX cells for the treatment of IC are ongoing in the U.S., Germany and Israel.

Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics ( UTHR ) or through research and clinical institutions. The cells from placenta, known as PLX cells, are derived using the company's proprietary PluriX therapy.

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corp. ( CELG ), is also doing research on stem cells derived from the human placenta as well as from the umbilical cord for the treatment of different diseases.

Pluristem currently carries a Zacks Rank #3 (Hold). Investors looking for better-ranked stocks in the broader healthcare sector might consider Actelion ( ALIOF ), carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PLURISTEM THERA (PSTI): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report


To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: PLX , IC , PSTI , UTHR , CELG

More from


Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by